|Articles|June 6, 2013
From ASCO: Updates in HER2-positive breast cancers
Author(s)Debu Tripathy
Advertisement
Debu Tripathy, MD, editor-in-chief of CURE, discusses preliminary studies on combining Herceptin (trastuzumab) with existing drugs to treat HER2-positive breast cancer. These highlighted studies were presented at the 2013 American Society of Clinical Oncology's annual meeting in Chicago.
Advertisement
Related Content
Advertisement
Advertisement
Trending on CURE
1
FDA Grants Breakthrough Therapy Designation to Ficerafusp Alfa in Head and Neck Cancer
2
What the FDA Approval of Inluriyo Means for Patients With Breast Cancer
3
What Subcutaneous Keytruda Means for Patients With Melanoma
4
Early Detection and Misconceptions in Lung Cancer
5
